Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Quality of life considerations are key when patients consider bariatric surgery

While weight loss surgery offers one of the best opportunities to improve health and reduce obesity related illnesses, the nearly 100,000 Americans who undergo bariatric surgery each year represent only a small fraction of people who are medically eligible for the procedure. Among those who have surgery, Caucasian Americans are twice as likely as African Americans to have weight loss surgery. On the surface, the data appear to signal racial disparity, but when researchers at Beth Israel Deaconess Medical Center dug deeper to ask why this variation exists, the answer was more complicated.

7 Jan 2014

Study: Long-term weight loss maintenance possible if individuals adhere to key health behaviors

Researchers from The Miriam Hospital have published one of the first studies of its kind to follow weight loss maintenance for individuals over a 10-year period. The results show that long-term weight loss maintenance is possible if individuals adhere to key health behaviors. The study is published in the January 2014 issue of the American Journal of Preventive Medicine.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Memorial Sloan-Kettering Cancer Center receives $90M in new financial support from Ludwig

Memorial Sloan-Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Announced today, the gift is among the largest publicly recorded gifts to cancer research made by a private organization, bringing the total funding to date for Ludwig Centers and endowed professorships at the six institutions to $900 million.

7 Jan 2014

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.

7 Jan 2014

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice University's Baker Institute for Public Policy and the University of Texas MD Anderson Cancer Center.

7 Jan 2014

New guidelines provide screening recommendations for people at higher risk of developing lung cancer

Alarmingly, more than 200,000 Americans will be diagnosed with lung cancer this year and nearly 160,000 people will die of the disease. In fact, according to the American Cancer Society, lung cancer takes more lives each year than colorectal, breast and prostate cancers combined.

7 Jan 2014

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

Cancer researchers at the University of Chicago and five other leading institutions will share equally in a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. Ludwig Cancer Research is an international community of researchers dedicated to pursuing life-changing discoveries to alter the course of cancer.

7 Jan 2014

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

7 Jan 2014

MD Anderson, Pfizer to advance development of immune-based treatment for cancer

The University of Texas MD Anderson Cancer Center and Pfizer will collaborate in the development of immune-based approaches to cancer treatment, the first such agreement made through MD Anderson's Moon Shots Program immunotherapy platform.

6 Jan 2014

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina.

6 Jan 2014

MIT receives $90M from Ludwig Cancer Research to strengthen interdisciplinary approach to cancer research

MIT has received $90 million from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, a gift that aims to transform basic research on metastasis, the process by which cancer cells spread from a primary tumor to distant sites in the body.

6 Jan 2014

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

Portage acquires approximately 54% equity in Biohaven

Portage Biotech Inc., is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited, a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.

6 Jan 2014

Johns Hopkins Kimmel Cancer Center scientists to receive $90M in new funding for cancer research

cientists at the Johns Hopkins Kimmel Cancer Center will receive $90 million in new funding as part of a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, to six U.S. institutions. The new award is among the largest for a single private gift to cancer research.

6 Jan 2014

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Aratana Therapeutics, Inc., a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for PIXUVRI® (pixantrone).

6 Jan 2014

Oncology News and Research

Further Reading

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Quality of life considerations are key when patients consider bariatric surgery

Study: Long-term weight loss maintenance possible if individuals adhere to key health behaviors

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Memorial Sloan-Kettering Cancer Center receives $90M in new financial support from Ludwig

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

New guidelines provide screening recommendations for people at higher risk of developing lung cancer

Researchers receive $540M from Ludwig Cancer Research to accelerate research on metastasis

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

MD Anderson, Pfizer to advance development of immune-based treatment for cancer

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

MIT receives $90M from Ludwig Cancer Research to strengthen interdisciplinary approach to cancer research

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Portage acquires approximately 54% equity in Biohaven

Johns Hopkins Kimmel Cancer Center scientists to receive $90M in new funding for cancer research

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

Event guide: 10th CAR-TCR Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News